Cellebrite DI (CLBT) Stock Price, News & Analysis

Company Overview

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows. Cellebrite DI also provides cloud collection tools to access data stored in online accounts and a suite of analytical modules that facilitate link analysis, timeline reconstruction and cross-case comparison. These solutions are complemented by professional services, training programs and technical support to ensure organizations can deploy and operate the technology effectively.

Founded in 1999 and headquartered in Petah Tikva, Israel, Cellebrite DI maintains key regional offices in North America, EMEA and APAC to serve a diverse global customer base. The company has played a role in high-profile forensic investigations, compliance audits and cybersecurity operations across multiple continents. Over time, it has expanded its portfolio through targeted research and development, strategic partnerships and acquisitions aimed at advancing its digital intelligence capabilities and addressing emerging challenges in data privacy and security.

Under the leadership of President and Chief Executive Officer Yossi Carmil, Cellebrite DI is governed by a board of directors chaired by cybersecurity veteran Amit Yoran. The management team combines expertise in digital forensics, software engineering and law enforcement to drive product innovation and maintain rigorous standards for data integrity and chain of custody. Through ongoing investment in R&D and a focus on customer-centric solutions, Cellebrite DI continues to evolve its offering to meet the needs of investigators and risk-management professionals worldwide.

Key Stats

• Today's Range: $13.15 to $13.64
• 50-Day Range: $11.03 to $15.30
• 52-Week Range: $11.02 to $20.45
• Volume: 648,130 shs
• Average Volume: 1.82 million shs
• Market Capitalization: $3.32 billion
• P/E Ratio: 42.89
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Moderate Buy

Cellebrite DI Stock Analysis - MarketRank™

Cellebrite DI scored higher than 62% of companies evaluated by MarketBeat, and ranked 304th out of 624 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellebrite DI has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellebrite DI has a consensus price target of $22.50, representing about 69.3% upside from its current price of $13.29.

Amount of Analyst Coverage

Cellebrite DI has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 18.60%

Earnings Growth

Earnings for Cellebrite DI are expected to grow by 18.60% in the coming year, from $0.43 to $0.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellebrite DI is 43.16, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellebrite DI is 43.16, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 73.20.

Price to Earnings Growth Ratio

Cellebrite DI has a PEG Ratio of 2.09. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cellebrite DI has a P/B Ratio of 6.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.29% of the float of Cellebrite DI has been sold short.

Short Interest Ratio / Days to Cover

Cellebrite DI has a short interest ratio ("days to cover") of 3.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellebrite DI has recently increased by 9.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellebrite DI does not currently pay a dividend.

Dividend Growth

Cellebrite DI does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Cellebrite DI this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CLBT on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cellebrite DI to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellebrite DI insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of Cellebrite DI is held by insiders.

Percentage Held by Institutions

45.88% of the stock of Cellebrite DI is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLBT Stock Analysis - Frequently Asked Questions

How have CLBT shares performed this year?

Cellebrite DI's stock was trading at $18.03 at the beginning of 2026. Since then, CLBT shares have decreased by 26.3% and is now trading at $13.2910.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) announced its quarterly earnings data on Wednesday, February, 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.14. Cellebrite DI's revenue was up 28.8% compared to the same quarter last year.
Read the conference call transcript.

Who are Cellebrite DI's major shareholders?

Top institutional shareholders of Cellebrite DI include Principal Financial Group Inc. (0.86%), Meitav Investment House Ltd. (0.78%), Bank of New York Mellon Corp (0.53%) and Walter Public Investments Inc. (0.18%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cellebrite DI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellebrite DI investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 2/11/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/14/2026
• J.P. Morgan 54th Annual Global Technology, Media and Communications Conference: 5/18/2026
• TD Cowen's 54th Annual Technology, Media & Telecom Conference: 5/27/2026
• 46th Annual William Blair Growth Stock Conference: 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: INTERNET SOFTWARE
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:CLBT
• CIK: 1854587
• Web: www.cellebrite.com
• Phone: 972-73-394-8000
• Fax: 972-3924-7104
• Employees: 1,285
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cellebrite DI: $22.50
• High Price Target: $25.00
• Low Price Target: $18.00
• Potential Upside/Downside: +69.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.31
• Trailing P/E Ratio: 42.95
• Forward P/E Ratio: 30.95
• P/E Growth: 2.09
• Net Income: $78.33 million
• Net Margins: 16.47%
• Pretax Margin: 19.06%
• Return on Equity: 20.43%
• Return on Assets: 10.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: $475.67 million
• Price / Sales: 6.98
• Cash Flow: $0.39 per share
• Price / Cash Flow: 33.75
• Book Value: $2.02 per share
• Price / Book: 6.59

Miscellaneous

• Outstanding Shares: 249,440,000
• Free Float: 235,222,000
• Market Cap: $3.32 billion
• Optionable: Optionable
• Beta: 1.15